(Adnkronos) - FORT COLLINS, Colo., Oct. 4, 2023 /PRNewswire/ -- Armis Biopharma, Inc. announced today that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to develop its proprietary Veriox® DECON chemical warfare agent (CWA) decontamination product for use in battlefield wounds. This will
The Armis Veriox® technology (Veriox® DECON) was found to be effective in neutralizing chemical warfare agents in two separate studies conducted by the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD).
"We are excited for the opportunity to bring a new technology to decontaminate chemical warfare agents for application in both civilian and military markets. Our unique proprietary solution, Veriox® DECON, offers several advantages over existing decontamination products for both individual application and for mass casualty settings because it can be rapidly dispensed with standard liquid dispensing systems that will allow first responders to quickly decontaminate multiple individuals," said Ted Ziemann, Chairman and CEO of Armis Biopharma. "Veriox® DECON is also environmentally safe in that it breaks down rapidly into harmless products and demonstrates a better safety profile than competitive products."
In November 2020, Armis Biopharma received a grant from the National Institutes of Health to develop Veriox® DECON to provide first responders working on mass-casualty decontamination, an effective, cost-efficient, fast application to neutralize chemical warfare agents on skin. Work on that application is currently in progress.
In addition to nerve agent decontamination, Veriox® DECON is also a highly effective antimicrobial agent, having shown excellent efficacy against biological warfare agents (BWAs) and drug resistant pathogens and has also been successfully tested against fentanyl.
About Armis Biopharma
Armis Biopharma, Inc is a privately held biopharmaceutical company headquartered in Fort Collins, CO that is devoted to developing and commercializing products that are effective in reducing the risk of infectious disease, decontaminating chemical warfare agents, and providing differentiated medical devices. Product development is focused on surface disinfection, human and animal wound care, oral care, food safety, and decontaminating chemical and biological warfare agents.
Armis introduced its first antimicrobial surface disinfectant called ArmiClenz® in June 2020, its FDA cleared VeriFixx® Small Bone Implant in November 2020, ArmiCare® hand sanitizer in 2021, ArmiVET® Animal Wound Wash in 2021, ArmiGard™ cleanser for oral devices in 2022, and most recently its FDA cleared VeriCyn® wound wash in May 2023. More pipeline products will follow starting in 2024.
For more information about Armis, please visit www.armisbiopharma.com.
General questions should be addressed to Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo..
Media contact:Karen Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
Logo - https://mma.prnewswire.com/media/2237912/Armis_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/armis-biopharma-announces-receipt-of-a-20-3-million-contract-with-the-defense-threat-reduction-agency-to-develop-veriox-decon-for-battlefield-wounds-301946277.html
